【摘要】 应用细胞融合技术成功地建立了3株持续高效分泌抗-HAV McAb的杂交瘤细胞株（AG₃,AD₂和AE₈株）,所得腹水中的抗-HAV滴度达1:128000～1:1024000。这3株McAb都能与粪便提取HAV和细胞培养HAV反应,且这种反应均能被甲肝病人恢复期血清阻断。这些McAb作用于HAV的不同抗原位点,其中AE₈ McAb具有中和HAV感染性的能性。这些McAb作包被抗体检测HAV时,所测的HAV滴度较人抗体作包被时测得的滴度高2～8倍。将AE₈ McAb标记酶后,用以检测Abbott药盒标化的50份甲肝IgM血清,49份结果一致,符合率98％。更多还原

【Abstract】 Three strain hybridomas (AG3, AD2, AE8) were developed by cell fusion technique. They secreted stably MeAbs against HAV with the titer of 1: 128000—1: 1024000 in ascites fluid by ELISA. All of these McAbs are of positive reaction on HAV derived from patient’s stools and cell culture, and this reaction can be inhibited by human anti HAV positive sera. The results of cell neutralization test and cross-blocking ELISA show that AE8 McAb is able to neutralize HAV infectivity, and that these McAbs recognize different epitopes of HAV. Compared with human auti-HAV, these auti-HAV McAbs, as coating antibody in ELISA, have higher detective ability. The titer of the HAV samples is 2—8 times higher than those of human anti-HAV. Using AE8 McAb-HRP and Abbott EIA kit to detect anti-HAV IgM in human sera, 49 out of 50 specimens are identical. The coincident rate is 98％.更多还原